Review of: "Polymerized Type I Collagen (Fibroquel) as a treatment for COVID-19, Mexican experience"

Kazuhiro Itoh

Potential competing interests: No potential competing interests to declare.

The authors presented the mechanism of action of polymerized type I collagen on COVID-19 and the results of a clinical trial conducted in Mexico; the search for effective treatments for COVID-19 will be necessary in the future.

Major comments

1. Based on the results of clinical trials to date, do the authors believe that polymerized type I collagen should be used for patients with COVID-19 of any severity, and what efficacy endpoint should be emphasized?
2. In Table 1, please also describe the intervention and the primary endpoint in detail. The timing of the clinical trial would also be important. Alternatively, it would be more useful to indicate which mutant strain was most commonly infected in the patients.
3. Did the clinical trials presented in this article show that polymerized type I collagen reduced the risk of hospitalization or severe disease?
4. Although it is stated that there were practically no side effects, please be more specific as to what specific side effects were seen and how often.

Minor comments

1. References should not include conference presentations. Instead, they should basically present the paper in which they were published.
2. The reviewer could not find any mention of polymerized type I collagen in the PAHO guidelines in Reference #2. Why did the authors cite the PAHO guidelines?
3. Does the fifth clinical trial in Table 1 have a reference? The reviewer could not find it using the search.